JPMorgan analyst Jessica Fye resumes coverage on Denali Therapeutics Inc. (NASDAQ: DNLI) with a Overweight rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage